Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

28.6%

4 terminated/withdrawn out of 14 trials

Success Rate

63.6%

-22.9% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed trials have results

Key Signals

1 recruiting6 with results

Enrollment Performance

Analytics

Phase 2

5(45.5%)

Phase 4

2(18.2%)

Early Phase 1

2(18.2%)

Phase 3

1(9.1%)

Phase 1

1(9.1%)

11Total

Phase 2(5)

Phase 4(2)

Early Phase 1(2)

Phase 3(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT05254405Phase 4Terminated

An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

Role: collaborator

NCT01246765Recruiting

National Pregnancy Registry for Psychiatric Medications

Role: collaborator

NCT05223829Phase 1Active Not Recruiting

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

Role: collaborator

NCT05366751Phase 2Terminated

A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

Role: lead

NCT06580444Phase 2Not Yet Recruiting

Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

Role: collaborator

NCT05173012Phase 2Completed

Study to Evaluate SAGE-324 in Participants With Essential Tremor

Role: lead

NCT05543746Completed

Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

Role: collaborator

NCT05314153Early Phase 1Completed

Effects Zulresso on Postpartum Psychosis

Role: collaborator

NCT04305275Phase 2Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

Role: lead

NCT04928703Early Phase 1Completed

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

Role: collaborator

NCT04537806Phase 3Terminated

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

Role: lead

NCT02277106Phase 2Completed

Evaluate SAGE-547 in Participants With Essential Tremor

Role: lead

NCT04025502Completed

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

Role: collaborator

NCT04273191Phase 4Withdrawn

A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)

Role: lead

All 14 trials loaded